The Top Three Holders Of GlaxoSmithKline plc (GSK)

GlaxoSmithKline plc (NYSE:GSK) reached 20.02% versus a 1-year low price of $34.52. The stock was last seen 1.05% higher, reaching at $41.43 on 07/10/2018. At recent session, the prices were hovering between $41.355 and $41.53. This company shares are 1.69% off its target price of $42.13 and the current market capitalization stands at $102.46B. The recent change has given its price a 2.56% lead over SMA 50 and -3.53% deficit over its 52-week high. The stock witnessed 1% gains, 1.1% gains and 10.78% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found GSK’s volatility during a week at 0.87% and during a month it has been found around 0.96%.

GlaxoSmithKline plc (GSK) Top Holders

Institutional investors currently hold around $11.29 billion or 11.4% in GSK stock. Look at its top three institutional owners. Dodge & Cox owns $1.99 billion in GlaxoSmithKline plc, which represents roughly 1.94% of the company’s market cap and approximately 17.63% of the institutional ownership. Similar statistics are true for the second largest owner, Royal Bank Of Canada, which owns 21,292,590 shares of the stock are valued at $873 million. The third largest holder is Fmr Llc, which currently holds $777.81 million worth of this stock and that ownership represents nearly 0.76% of its market capitalization.

GlaxoSmithKline plc 13F Filings

At the end of March reporting period, 378 institutional holders increased their position in GlaxoSmithKline plc (NYSE:GSK) by some 26,743,730 shares, 331 decreased positions by 24,593,134 and 136 held positions by 224,129,490. That puts total institutional holdings at 275,466,354 shares, according to SEC filings. The stock grabbed 95 new institutional investments totaling 9,214,731 shares while 81 institutional investors sold out their entire positions totaling 4,938,995 shares.

GlaxoSmithKline plc (NYSE:GSK) Insider Trades

Multiple company employees have indulged in significant insider trading. GlaxoSmithKline plc disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Former 10% Owner Glaxosmithkline Plc has sold 503,150 shares of GlaxoSmithKline plc (GSK) in trading session dated Feb. 23, 2015. These shares are worth $11,069,300 and were traded at $22 each. The SEC filing shows that Glaxosmithkline Plc performed a sale of 50,000 shares. The 10% Owner disposed these shares by way of transaction on Dec. 18, 2014. The company’s shares were given away at $21.14 per share worth to an income of some $1,057,000 on account of Glaxosmithkline Plc.

Former 10% Owner, Glaxosmithkline Plc, sold 11,315,825 common shares of GlaxoSmithKline plc (GSK) in the open market. In a transaction dated Oct. 27, 2014, the shares were put up for sale at an average price of $5.29, raking in a sum of $59,860,714. After this sale, common shares of GSK are directly owned by the insider, with total stake valued at $.

In the transaction dated Apr. 01, 2014, the great number of shares acquired came courtesy the 10% Owner; Glaxosmithkline Plc added a total of 103,762 shares at an average price of $12, amounting to approximately $1,245,144. The insider now directly owns 1,989,598 shares worth $82,429,045.

GlaxoSmithKline plc (GSK) Analyst Guide

Several analysts have released their opinion on GlaxoSmithKline plc (NYSE:GSK), with 3 analysts believing it is a strong buy. Whereas 4 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 1 strong sell ratings, collectively assigning a 2.5 average brokerage recommendation.